Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity

American Journal of Physiology - Renal Physiology

Volumn 313, Issue 4, 2017, Pages F951-F954

  Saly, Danielle L ^a   Perazella, Mark A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute kidney injury; Biomarkers; Nephrotoxicity; SGLT2 inhibitors; Urine microscopy

Indexed keywords

ANGIOTENSIN ANTAGONIST; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIURETIC AGENT; EMPAGLIFLOZIN; NONSTEROID ANTIINFLAMMATORY AGENT; RENIN INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

ACUTE KIDNEY FAILURE; ARTICLE; CHRONIC KIDNEY FAILURE; HEMODIALYSIS; HUMAN; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED;

ACUTE KIDNEY INJURY; ANIMALS; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85030530784     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00250.2017     Document Type: Article

References (20)

1. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG RENAL Trial Investigators. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2: 369-384, 2014. doi:10.1016/S2213-8587(13)70208-0.
2. Bjornstad P, Lanaspa MA, Ishimoto T, Kosugi T, Kume S, Jalal D, Maahs DM, Snell-Bergeon JK, Johnson RJ, Nakagawa T. Fructose and uric acid in diabetic nephropathy. Diabetologia 58: 1993-2002, 2015. doi:10.1007/s00125-015-3650-4.
3. Blank M, De Felice A, Goodsaid F, Harlow P, Hausner E, Jacobson-Kram D, Taylor W, Thompson A, Throckmorton D, and Xiao S. Review of Qualification Data for Biomarkers of Nephrotoxicity Submitted by the Predictive Safety Testing Consortium. Rockville, MD: U.S. Food and Drug Administration, 2009.
4. Bonventre JV, Vaidya VS, Schmouder R, Feig P, Dieterle F. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol 28: 436-440, 2010. doi:10.1038/nbt0510-436.
5. Chao EC, Henry RR. SGLT2 inhibition—a novel strategy for diabetes treatment. Nat Rev Drug Discov 9: 551-559, 2010. doi:10.1038/nrd3180.
6. Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol 12: 711-712, 2016. doi:10.1038/nrneph.2016.159.
7. Hahn K, Kanbay M, Lanaspa MA, Johnson RJ, Ejaz AA. Serum uric acid and acute kidney injury: a mini review. J Adv Res 8: 529-536, 2017. doi:10.1016/j.jare.2016.09.006.
8. Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 28: 368-375, 2017. doi:10.1681/ASN.2016030278.
9. Jang KJ, Mehr AP, Hamilton GA, McPartlin LA, Chung S, Suh KY, Ingber DE. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr Biol 5: 1119-1129, 2013. doi:10.1039/c3ib40049b.
10. Kitamura H, Yamauchi A, Sugiura T, Matsuoka Y, Horio M, Tohyama M, Shimada S, Imai E, Hori M. Inhibition of myo-inositol transport causes acute renal failure with selective medullary injury in the rat. Kidney Int 53: 146-153, 1998. doi:10.1046/j.1523-1755.1998.00747.x.
11. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993. doi:10.1056/NEJM199311113292004.
12. O’Neill J, Fasching A, Pihl L, Patinha D, Franzén S, Palm F. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol 309: F227-F234, 2015. doi:10.1152/ajprenal.00689.2014.
13. Paoli R, Samitier J. Mimicking the Kidney: A Key Role in Organ-on-Chip Development. Micromachines (Basel) 7: 126, 2016. doi:10.3390/mi7070126.
14. Perazella MA, Coca SG, Hall IE, Iyanam U, Koraishy M, Parikh CR. Urine microscopy is associated with severity and worsening of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol 5: 402-408, 2010. doi:10.2215/CJN.06960909.
15. Perazella MA, Coca SG, Kanbay M, Brewster UC, Parikh CR. Diagnostic value of urine microscopy for differential diagnosis of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol 3: 1615- 1619, 2008. doi:10.2215/CJN.02860608.
16. Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, Broedl UC; on behalf of the EMPA-REG MONO trial investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1: 208-219, 2013. doi:10.1016/S2213-8587(13)70084-6.
17. 17a.U.S. Food and Drug Administration. FDA strengthens kidney warning for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). https://www.fda.gov/Drugs/DrugSafety/ucm505860.htm. [accessed May 9, 2017].
18. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in Type 2 diabetes. N Engl J Med 375: 323-334, 2016. doi:10.1056/NEJMoa1515920. https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27806236&dopt= Abstract.
19. Wilmer MJ, Ng CP, Lanz HL, Vulto P, Suter-Dick L, Masereeuw R. Kidney-on-a-chip technology for drug-induced nephrotoxicity screening. Trends Biotechnol 34: 156-170, 2016. doi:10.1016/j.tibtech.2015.11.001.
20. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med 373: 2117-2128, 2015. doi:10.1056/NEJMoa1504720.